2022

Schuhenn, J., Meister, T. L., Todt, D., Bracht, T., Schork, K., Billaud, J. N., Elsner, C., Heinen, N., Karakoese, Z., Haid, S., Kumar, S., Brunotte, L., Eisenacher, M., Di, Y., Lew, J., Falzarano, D., Chen, J., Yuan, Z., Pietschmann, T., Wiegmann, B., Uebner, H., Taube, C., Le-Trilling, V. T. K., Trilling, M., Krawczyk, A., Ludwig, S., Sitek, B., Steinmann, E., Dittmer, U., Lavender, K. J., Sutter, K., and Pfaender, S. (2022) Differential interferon-α subtype induced immune signatures are associated with suppression of SARS-CoV-2 infection, Proc Natl Acad Sci U S A 119.

Schreiber, A., Viemann, D., Schoning, J., Schloer, S., Mecate Zambrano, A., Brunotte, L., Faist, A., Schofbanker, M., Hrincius, E., Hoffmann, H., Hoffmann, M., Pohlmann, S., Rescher, U., Planz, O., and Ludwig, S. (2022) The MEK1/2-inhibitor ATR-002 efficiently blocks SARS-CoV-2 propagation and alleviates pro-inflammatory cytokine/chemokine responses, Cell Mol Life Sci 79, 65.

Chaudhry, M. Z., Eschke, K., Hoffmann, M., Grashoff, M., Abassi, L., Kim, Y., Brunotte, L., Ludwig, S., Kroger, A., Klawonn, F., Pohlmann, S. H., and Cicin-Sain, L. (2022) Rapid SARS-CoV-2 Adaptation to Available Cellular Proteases, J Virol, jvi0218621.

2021

Schloer, S*., Brunotte, L*., Goretzko, J., Mecate-Zambrano, A., Korthals, N., Gerke, V., Ludwig, S., and Rescher, U. (2020) Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine, Emerg Microbes Infect 9, 2245-2255. *shared first author

Brunotte, L., Zheng, S., Mecate-Zambrano, A., Tang, J., Ludwig, S., Rescher, U., and Schloer, S. (2021) Combination Therapy with Fluoxetine and the Nucleoside Analog GS-441524 Exerts Synergistic Antiviral Effects against Different SARS-CoV-2 Variants In Vitro, Pharmaceutics 13.

Schloer, S., Brunotte, L., Mecate-Zambrano, A., Zheng, S., Tang, J., Ludwig, S., and Rescher, U. (2021) Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro, Br J Pharmacol 178, 2339-2350.

Boergeling, Y., Brunotte, L., and Ludwig, S. (2021) Dynamic phospho-modification of viral proteins as a crucial regulatory layer of influenza A virus replication and innate immune responses, Biol Chem 402, 1493-1504.

Günl, F., Mecate-Zambrano, A., Rehländer, S., Hinse, S., Ludwig, S., and Brunotte, L. (2021) Shooting at a Moving Target-Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development, Vaccines (Basel) 9.

Kumar, S., Çalışkan, D. M., Janowski, J., Faist, A., Conrad, B. C. G., Lange, J., Ludwig, S., and Brunotte, L. (2021) Beyond Vaccines: Clinical Status of Prospective COVID-19 Therapeutics, Front Immunol 12, 752227.

Bertoglio, F., Meier, D., Langreder, N., Steinke, S., Rand, U., Simonelli, L., Heine, P. A., Ballmann, R., Schneider, K. T., Roth, K. D. R., Ruschig, M., Riese, P., Eschke, K., Kim, Y., Schackermann, D., Pedotti, M., Kuhn, P., Zock-Emmenthal, S., Wohrle, J., Kilb, N., Herz, T., Becker, M., Grasshoff, M., Wenzel, E. V., Russo, G., Kroger, A., Brunotte, L., Ludwig, S., Fuhner, V., Kramer, S. D., Dubel, S., Varani, L., Roth, G., Cicin-Sain, L., Schubert, M., and Hust, M. (2021) SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface, Nat Commun 12, 1577.

2020

Schreiber, A., Boff, L., Anhlan, D., Krischuns, T., Brunotte, L., Schuberth, C., Wedlich-Soldner, R., Drexler, H., and Ludwig, S. (2020) Dissecting the mechanism of signaling-triggered nuclear export of newly synthesized influenza virus ribonucleoprotein complexes, Proc Natl Acad Sci U S A 117, 16557-16566.

Boff L., Schreiber A., da Rocha Matos A., Del Sarto J., Brunotte L., Munkert J., Ottini MF., Ramos GS., Kreis W., Braga FC., Alves RJ., de Padua RM., Somoes CMO., Ludwig S. Semisynthetic cardenolides acting as antiviral inhibitors of influenza A virus replication by preventing polymerase complex formation. Molecules 2020.

Schloer S., Brunotte L*., Goretzko J., Mecate-Zambrano A., Korthals N., Gerke V., Ludwig S., Rescher U. Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine. EMI, 2020. *shared first author

Schreiber A, Liedmann S, Brunotte L, Anhlan D, Ehrhardt C, Ludwig S. Type I interferon antagonistic properties of influenza B virus polymerase proteins. Cell Microbiol. 2020;22(2):e13143.

2019    

Schloer S, Hubel N, Masemann D, Pajonczyk D, Brunotte L, Ehrhardt C, Brandenburg LO, Ludwig S, Gerke V, Rescher U. 2019. The annexin A1/FPR2 signaling axis expands alveolar macrophages, limits viral replication, and attenuates pathogenesis in the murine influenza A virus infection model. FASEB J 33: 12188-99

Schloer S, Goretzko J, Kuhnl A, Brunotte L, Ludwig S, Rescher U. 2019. The clinically licensed antifungal drug itraconazole inhibits influenza virus in vitro and in vivo. Emerg Microbes Infect 8: 80-93

Matos ADR, Wunderlich K, Schloer S, Schughart K, Geffers R, Seders M, Witt M, Christersson A, Wiewrodt R, Wiebe K, Barth P, Hocke A, Hippenstiel S, Honzke K, Dittmer U, Sutter K, Rescher U, Rodionycheva S, Matera N, Ludwig S, Brunotte L. 2019. Antiviral potential of human IFN-alpha subtypes against influenza A H3N2 infection in human lung explants reveals subtype-specific activities. Emerg Microbes Infect 8: 1763-76

2018

Krischuns T, Günl F, Henschel L, Binder M, Willemsen J, Schloer S, Rescher U, Gerlt V, Zimmer G, Nordhoff C, Ludwig S, Brunotte L: Phosphorylation of TRIM28 enhances the expression of IFN-β and proinflammatory cytokines during HPAIV infection in human lung epithelial cells. Front. Immunol 2018.

Gabriel M, Adomeh DI, Ehimuan J, Oyakhilome J, Omomoh EO, Ighodalo Y, Olokor T, Bonney K, Pahlmann M, Emmerich P, Lelke M, Brunotte L, Olschlager S, Thome-Bolduan C, Becker-Ziaja B, Busch C, Odia I, Ogbaini-Emovon E, Okokhere PO, Okogbenin SA, Akpede GO, Schmitz H, Asogun DA, Gunther S. 2018. Development and evaluation of antibody-capture immunoassays for detection of Lassa virus nucleoprotein-specific immunoglobulin M and G. PLoS Negl Trop Dis 12: e0006361

2016

Brunotte L, Beer M, Horie M, Schwemmle M. 2016. Chiropteran influenza viruses: flu from bats or a relic from the past? Curr Opin Virol 16: 114-9

2015

Weber M, Sediri H, Felgenhauer U, Binzen I, Banfer S, Jacob R, Brunotte L, Garcia-Sastre A, Schmid-Burgk JL, Schmidt T, Hornung V, Kochs G, Schwemmle M, Klenk HD, Weber F. 2015. Influenza virus adaptation PB2-627K modulates nucleocapsid inhibition by the pathogen sensor RIG-I. Cell Host Microbe 17: 309-19

2014

Brunotte L, Flies J, Bolte H, Reuther P, Vreede F, Schwemmle M: The nuclear export protein of H5N1 influenza A viruses recruits Matrix 1 (M1) protein to the viral ribonucleoprotein for nuclear export. J Biol Chem. 2014. 18;289(29):20067-77

Reuther P, Giese S, Götz V, Kilb N, Mänz B, Brunotte L, Schwemmle M: Adaptive mutations in the nuclear export protein of human-derived H5N1 strains facilitate the polymerase-enhancing conformation. J. Virol. 2014 Jan;88(1):263-71.

2013

Mänz B., Schwemmle M., Brunotte L: Adaptation of avian influenza A virus polymerase in mammals to overcome the host species barrier. J.Virol. 2013 Jul;87(13):7200-9.

2012

Mänz B, Brunotte L, Reuther P, Schwemmle M: Adaptive mutations in NEP compensate for defective H5N1 RNA replication in cultured human cells in vitro. Nat Commun. 2012;3:802

2011

Reuther P, Mänz B, Brunotte L, Schwemmle M, Wunderlich K.: Targeting of the influenza A virus polymerase PB1-PB2 interface indicates strain-specific assembly differences.   J Virol. 2011 Dec;85(24):13298-309.

Brunotte L, Kerber R, Shang W, Hauer F, Hass M, Gabriel M, Lelke M, Busch C, Stark H, Svergun D, Betzel C, Perbandt M, Günther S: Structure of the Lassa Virus Nucleoprotein Revealed by X-ray Chrystallography, Small-angle X-ray Scattering, and Electron Microscopy. J Biol Chem. 2011 Nov 4;286(44):38748-56.

Brunotte L, Lelke M, Hass M, Kleinsteuber K, Becker-Ziaja B, Günther S.: Domain structure of Lassa Virus L Protein, J Virol. 2011 Jan;85(1):324-33. doi: 10.1128/JVI.00721-10

2010

Lelke M, Brunotte L, Busch C, Günther S: An N-terminal Region of Lassa Virus L Protein plays a critical role in transcription but not replication of the virus genome.

J. Virol. 2010 Feb;84(4):1934-44. doi: 10.1128/JVI.01657-09.